. Author manuscript; available in PMC: 2015 Feb 1.

Published in final edited form as: J Pediatr Gastroenterol Nutr. 2014 Feb;58(2):215–221. doi: 10.1097/MPG.0b013e3182a98df2

Table 3.

Comparison of baseline factors between infliximab outcome groups

Variable n (%) or median (IQR)	Infliximab Failure		P-value	Infliximab Dose Escalation		P-value
Variable n (%) or median (IQR)	Yes	No	P-value	Yes	No	P-value
Male gender	10 (56%)	5 (46%)	0.71	10 (56%)	5 (46%)	0.71
BMI z-score	0.0 (−1.8,−0.4)	−1.3 (−1.6,−1.0)	0.16	−1.4 (−1.9,−0.1)	0.0 (−1.0,0.7)	0.01
Albumin (g/dL)	3.1 (2.6,3.2)	3.2 (2.4,3.4)	0.57	3.0 (2.6,3.1)	3.3 (3.0,3.6)	0.03
ESR (mm/hr)	50 (27,75)	38 (23,52)	0.42	53 (37,74)	23 (21,33)	0.002
Hemoglobin (g/dL)	9.5 (7.4,11.1)	9.5 (8.9,11.2)	0.58	9.3 (7.9,10.9)	10.2 (7.0,11.2)	0.72
Disease Duration (yrs)	1 (0,2.5)	0.7 (0,4.25)	0.81	1 (0,2.5)	1 (0,3)	0.73

IQR, interquartile range; BMI, body mass index